No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: FDA Approves Eli Lilly’s Ebglyss® for Eczema
On 13 September 2024, Eli Lilly announced that its Ebglyss® (lebrikizumab-lbkz) received FDA approval for adults and children 12 years and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription...